A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) is a phase 1/2 interventional study registered as NCT06953960 by AbbVie, with 325 participants planned, started 2025-07-23 and due to reach its primary completion in 2030-12. Interventions recorded: Surzetoclax, Daratumumab, Dexamethasone, Pomalidomide, Etentamig. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.